School of Population and Global Health, University of Western Australia, Crawley, WA, Australia.
Medical School, University of Western Australia, Crawley, WA, Australia.
BMC Cardiovasc Disord. 2023 Jan 16;23(1):25. doi: 10.1186/s12872-022-03020-x.
Readmissions within 30 days after heart failure (HF) hospitalisation is considered an important healthcare quality metric, but their impact on medium-term mortality is unclear within an Australian setting. We determined the frequency, risk predictors and relative mortality risk of 30-day unplanned readmission in patients following an incident HF hospitalisation.
From the Western Australian Hospitalisation Morbidity Data Collection we identified patients aged 25-94 years with an incident (first-ever) HF hospitalisation as a principal diagnosis between 2001 and 2015, and who survived to 30-days post discharge. Unplanned 30-day readmissions were categorised by principal diagnosis. Logistic and Cox regression analysis determined the independent predictors of unplanned readmissions in 30-day survivors and the multivariable-adjusted hazard ratio (HR) of readmission on mortality within the subsequent year.
The cohort comprised 18,241 patients, mean age 74.3 ± 13.6 (SD) years, 53.5% males, and one-third had a modified Charlson Comorbidity Index score of ≥ 3. Among 30-day survivors, 15.5% experienced one or more unplanned 30-day readmission, of which 53.9% were due to cardiovascular causes; predominantly HF (31.4%). The unadjusted 1-year mortality was 15.9%, and the adjusted mortality HR in patients with 1 and ≥ 2 cardiovascular or non-cardiovascular readmissions (versus none) was 1.96 (95% confidence interval (CI) 1.80-2.14) and 3.04 (95% CI, 2.51-3.68) respectively. Coexistent comorbidities, including ischaemic heart disease/myocardial infarction, peripheral arterial disease, pneumonia, chronic kidney disease, and anaemia, were independent predictors of both 30-day unplanned readmission and 1-year mortality.
Unplanned 30-day readmissions and medium-term mortality remain high among patients who survived to 30 days after incident HF hospitalisation. Any cardiovascular or non-cardiovascular readmission was associated with a two to three-fold higher adjusted HR for death over the following year, and various coexistent comorbidities were important associates of readmission and mortality risk. Our findings support the need to optimize multidisciplinary HF and multimorbidity management to potentially reduce repeat hospitalisation and improve survival.
在心力衰竭(HF)住院后 30 天内再次入院被认为是医疗质量的一个重要指标,但在澳大利亚的背景下,其对中期死亡率的影响尚不清楚。我们确定了在 2001 年至 2015 年间因首次 HF 住院的患者出院后 30 天内再次出现计划外再入院的频率、风险预测因素和相对死亡率风险。
我们从西澳大利亚住院发病率数据收集库中确定了年龄在 25-94 岁之间的患者,他们患有首次 HF 住院,且在出院后 30 天内存活。计划外 30 天再入院根据主要诊断进行分类。Logistic 和 Cox 回归分析确定了 30 天幸存者中计划外再入院的独立预测因素,以及随后一年内因再入院而导致的多变量调整后的死亡率风险比(HR)。
该队列包括 18241 名患者,平均年龄为 74.3±13.6(SD)岁,53.5%为男性,三分之一的患者改良 Charlson 合并症指数评分≥3。在 30 天幸存者中,15.5%经历了一次或多次计划外 30 天再入院,其中 53.9%是由于心血管原因引起的;主要是心力衰竭(31.4%)。未调整的 1 年死亡率为 15.9%,在因 1 次或≥2 次心血管或非心血管再入院(与无再入院相比)的患者中,1 年死亡率 HR 分别为 1.96(95%置信区间[CI]为 1.80-2.14)和 3.04(95%CI,2.51-3.68)。共存的合并症,包括缺血性心脏病/心肌梗死、外周动脉疾病、肺炎、慢性肾脏病和贫血,是 30 天计划外再入院和 1 年死亡率的独立预测因素。
在因 HF 住院后存活 30 天的患者中,计划外 30 天再入院和中期死亡率仍然很高。任何心血管或非心血管再入院都与随后一年因死亡而调整后的 HR 增加两到三倍相关,而各种共存的合并症是再入院和死亡率风险的重要相关因素。我们的研究结果支持需要优化多学科 HF 和多合并症管理,以潜在减少重复住院和提高生存率。